Monoclonal antibodies (mAbs) is one of the fast-growing classes of pharmaceutical molecules capable of treating a wide variety of diseases. In industry, the fed-batch bioreactor is commonly used for upstream monoclonal antibody production. However, due to complicated relations between operating conditions and cell growth, bioreactor scale-up is time-consuming. This presentation will introduce the model-based approach to simulate small- and large-scale bioreactor operations and illustrate how to accelerate process scale-up during the technical transfer process.
Learning Objectives:
Upon completion, participants will be able to identify the potential gaps during the bioreactor scale-up process.
Upon completion, participants will be able to understand the strategy of using modelling approaches to resolve bioreactor related questions.
Upon completion, participants will be able to recognize multiple modeling methodologies.